Inflammatory Bowel Disease-Competition Increases for the Biologics

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-11-27

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Ulcerative colitis and Crohn's disease are the primary constituents of Inflammatory Bowel Disease, which is estimated to affect approximately 1.8 million people in the seven major markets. Eight years after the launch of Remicade in Crohn's disease the next generation of anti-TNF's are poised for approval, but the anti-TNF class will soon be under attack from novel cytokine therapies.


Scope

  • Ulcerative colitis and Crohn's disease ten-year forecasts, contrasted against estimated total brand sales
  • Sales and volume estimates by indication from 2005-2015 for the US, combined five major EU markets (France, Germany, Italy, Spain, UK) and Japan
  • Analysis of late-stage pipeline products for Crohn's disease and ulcerative colitis
  • Discussion of future events that affect the sales and volume of key brands


    • Report Highlights
    The battle between Cimzia and Humira will depend on efficacy, convenience and cost. Datamonitor believes Humira's efficacy in all patient segments, including low CRP patients and it's wealth of safety data, added to the fact that it has already been used off-label, will win out over Cimzia superior dosing regime.

    Patient segmentation is expected to be crucial in the future of IBD treatment. The maintenance of clinical remission and mucosal healing should be considered key outcomes, which should be targeted towards specific groups to aid product differentiation.

    Ulcerative colitis patients respond better than Crohn's patients to 5-ASAs and surgery, which can effectively be a cure, therefore Datamonitor predicts less success for the biologics in ulcerative colitis. Companies should be aware that IBD is estimated to be neither the most prevalent or profitable indication for autoimmune biologics.


    Reasons to Purchase

  • Compare inflammatory bowel disease forecasts with total brand sales for key existing products
  • Estimate the size of the Crohn's disease and ulcerative colitis markets to 2015
  • Benchmark late-stage pipeline products against the market leader

    • Table of Contents

    Other users found this report page using the following search terms: IBD colitis inflammatory bowel crohns ibd cimzia disease crohns biologics ulcerative remicade colitis sales inflammatory

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.